Statistics for Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors
Total visits
| views | |
|---|---|
| Phase II trial of brentuximab vedotin in relapsed/refractory germ cell tumors | 4 |
Total visits per month
| views | |
|---|---|
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
File Visits
| views | |
|---|---|
| java.util.UUID:70f348eb-cf68-459d-919f-93bd2b636067 | 34 |
| nihms-1835750.pdf | 25 |
| java.util.UUID:ecbbb839-ff3c-4ae6-b8f2-aa1da01eeea0 | 9 |
| java.util.UUID:e5c418a8-4e6a-48a0-9028-61320fc14d9e | 5 |
Top country views
| views | |
|---|---|
| United States | 3 |
| United Kingdom | 1 |
Top city views
| views | |
|---|---|
| Indianapolis | 2 |
| Boston | 1 |
| Louth | 1 |